XFOR READ THE FULL XFOR RESEARCH REPORT Business Update Full Enrollment of Phase 3 4WARD Trial Expected in 2H25 X4 ...

Q4 2024 Earnings Call Transcript March 25, 2025 X4 Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0 ...

In the assessment of 12-month price targets, analysts unveil insights for X4 Pharmaceuticals, presenting an average target of ...

Shares of NASDAQ XFOR opened at $0.27 on Wednesday. The company has a 50-day simple moving average of $0.44 and a 200-day simple moving average of $0.53. The company has a debt-to-equity ratio of ...

HC Wainwright reiterated their buy rating on shares of X4 Pharmaceuticals (NASDAQ:XFOR – Free Report) in a research note published on Thursday morning,Benzinga reports. They currently have a $1. ...

Phase 3 4WARD trial in chronic neutropenia now activated at ~90% of targeted trial sites; full enrollment expected in 3Q or ...

BOSTON (AP) — BOSTON (AP) — X4 Pharmaceuticals, Inc. (XFOR) on Tuesday reported a loss of $39.8 million in its fourth quarter. On a per-share basis, the Boston-based company said it had a loss of 20 ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on X4 Pharmaceuticals (XFOR – Research Report) and ...

The latest price target for X4 Pharmaceuticals (NASDAQ:XFOR) was reported by HC Wainwright & Co. on March 27, 2025. The analyst firm set a price target for $1.50 expecting XFOR to rise to within ...

In the last three months, 4 analysts have published ratings on X4 Pharmaceuticals (NASDAQ:XFOR), offering a diverse range of perspectives from bullish to bearish. The following table encapsulates ...